## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol  XCYTE THERAPIES INC [ XCYT ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SPIEGELMAN DANIEL K													X Directo	or		10% Ow	/ner		
(Last) (First) (Middle) 3172 PORTER DRIVE					Date o		Trans	saction (Mor	nth/D	Day/Year)		Officer below)	(give title		Other (s below)	pecify			
						f Ame	ndment [	Date	of Original F	iled	(Month/Da	6.1	6. Individual or Joint/Group Filing (Check Applicable						
(Street) PALO ALTO CA 94			94304		4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Line)  X Form filed by One Reporting Person Form filed by More than One Reporting						
(City) (State) (Zip)			(Zip)										Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Executio			Code (Instr.		4. Securities Acquired ( Disposed Of (D) (Instr. 3 5)		ed (A) or tr. 3, 4 and	Beneficia Owned F	s ally following	Form:	Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	mount (A) or (D)		Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)			e and 7. Title and Ar of Securities Underlying Derivative Ser (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Ownership Form:	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		expiration pate	Title	Amount or Number of Shares						
Director (Stock Option Right to Buy) <sup>(1)</sup>	\$0.63	06/17/2005			A		10,000		(2)	0	6/17/2015	Common	10,000	\$0	10,000	)	D		
Director (Stock Option Right to Buy) <sup>(1)</sup>	\$0.63	06/17/2005			A		2,500		(2)	0	6/17/2015	Common	2,500	\$0	12,500	)	D		
Director (Stock Option	\$0.63	06/17/2005			A		2,500		(2)	0	6/17/2015	Common	2,500	\$0	15,000		D		

## **Explanation of Responses:**

Buy)(1)

- 1. Option grant is automatic under the Company's Amended and Restated 2003 Directors' Stock Option Plan.
- 2. 1/24th of the total number of shares shall vest each month beginning one month from the vesting commencement date in successive equal monthly installments with total vesting occuring on the two-year anniversary date of the vesting commencement date.

By: Kathi Cordova, under POA 06/17/2005

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.